CAR T Therapy Shows Early Promise in Stiff Person Syndrome - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

CAR T Therapy Shows Early Promise in Stiff Person Syndrome

  • November 18, 2026

  • 3 min

Share

Clinical Scorecard: Mivocabtagene Autoleucel Studied in Phase 2 Trial for Stiff Person Syndrome

At a Glance

CategoryDetail
ConditionStiff person syndrome (SPS), a rare, progressive autoimmune neurological disorder characterized by muscle stiffness and painful spasms.
Key MechanismsMivocabtagene autoleucel is an autologous CD19-directed CAR T-cell therapy. In the trial, complete peripheral B-cell depletion was observed by day five; among patients with elevated GAD65 autoantibodies, median levels fell 56% by week 16.
Target PopulationAdults with antibody-positive SPS who responded inadequately to previous immunomodulatory treatment.
Care SettingMulticenter, open-label phase 2 trial: 27 participants enrolled, and 26 received a single infusion after low-dose lymphodepleting chemotherapy.

Key Highlights

  • At week 16, the median improvement in the timed 25-foot walk test, the primary efficacy endpoint, was 45.6%.
  • More than 80% of participants achieved clinically meaningful improvements in walking speed.
  • Eight of 12 participants who initially required walking aids no longer needed them.
  • Significant improvements were reported across secondary measures of stiffness, hypersensitivity, disability, and mobility.
  • All 26 treated participants remained free of SPS-directed immunomodulatory or immunosuppressive therapies at latest follow-up; median follow-up was 6.5 months.
  • The study authors state that long-term follow-up to substantiate durability of benefits is in progress.

Guideline-Based Recommendations

Diagnosis

  • The source does not provide diagnostic recommendations.

Management

  • The trial administered one infusion of mivocabtagene autoleucel after low-dose lymphodepleting chemotherapy.
  • The source describes IVIg, plasmapheresis, and rituximab as existing treatments that often provide incomplete or temporary relief.

Monitoring & Follow-up

  • The trial assessed walking ability, stiffness, hypersensitivity, disability, and mobility.
  • Biomarker analyses included peripheral B-cell depletion and GAD65 autoantibody levels.
  • The study authors state that long-term follow-up to substantiate durability is in progress.

Risks

  • Cytokine release syndrome occurred in 92.3% of treated patients; all cases were grade 1 or 2.
  • Three patients experienced grade 1 neurotoxicity.
  • Grade 3 or 4 neutropenia occurred in five patients (19.2%).
  • No deaths or adverse-event-related study discontinuations were reported.

Patient & Prescribing Data

The KYSA-8 trial enrolled 27 adults with antibody-positive SPS and inadequate response to previous immunomodulatory treatment; 26 received treatment.

Participants received one infusion of mivocabtagene autoleucel after low-dose lymphodepleting chemotherapy. All treated participants were free of SPS-directed immunomodulatory or immunosuppressive therapies at latest follow-up; median follow-up was 6.5 months.

Clinical Best Practices

    Related Resources & Content

    Original Source(s)

    Related Content